Subcutaneous trastuzumab: drug development and current position.
HER2-positive breast cancer, accounting for 15 % of the total breast cancer patient population, carries in itself a bad prognosis, which has now become much better after the advent of anti-HER2 drugs. HER2-targeted therapy has significantly improved disease free- and overall survival in HER2-positive breast cancer, and has rendered better disease control both in the early and advanced disease setting. Trastuzumab treatment duration is often prolonged and poses significant time and resource challenges both on the treatment institutions and on the patient. The recent development of a subcutaneous formulation has meant a significant advance in this respect. We review the drug development of the compound and the current evidence on its use.
Hematology and Medical Oncology Department, Hospital Clínico Universitario de Valencia, Avda. Blasco Ibáñez 17, 46010, Valencia, Spain, paloma_martin@comv.es.
P
P
Martín Martorell
B
B
Bermejo de Las Heras
J A
JA
Pérez-Fidalgo
M
M
Huerta Alvaro
M
M
Martín
J
J
Albanell
A
A
Lluch Hernández
D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D055808:Drug Discovery; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D000068878:Trastuzumab
D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab